Prometheus Biosciences Inc. (RXDX) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Prometheus Biosciences In...

    NASDAQ: RXDX · Real-Time Price · USD
    199.92
    0.18 (0.09%)
    At close: Jun 15, 2023, 10:00 PM

    Prometheus Biosciences Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2022 FY 2021
    Period Ending Dec 31, 2022 Dec 31, 2021
    Revenue
    		 6.81M 3.13M
    Cost of Revenue
    		 n/a n/a
    Gross Profit
    		 6.81M 3.13M
    Operating Income
    		 -145.78M -87.8M
    Interest Income
    		 4.03M 108K
    Pretax Income
    		 -141.75M -90.19M
    Net Income
    		 -141.75M -89.94M
    Selling & General & Admin
    		 39.74M 28.5M
    Research & Development
    		 112.85M 62.43M
    Other Expenses
    		 n/a n/a
    Operating Expenses
    		 152.59M 90.93M
    Interest Expense
    		 n/a 861K
    Selling & Marketing Expenses
    		 n/a n/a
    Cost & Expenses
    		 152.59M 90.93M
    Income Tax Expense
    		 n/a -258K
    Shares Outstanding (Basic)
    		 40.62M 31.33M
    Shares Outstanding (Diluted)
    		 40.62M 31.33M
    EPS (Basic)
    		 -3.49 -2.87
    EPS (Diluted)
    		 -3.49 -2.87
    EBITDA
    		 -145.78M -87.8M
    EBIT
    		 -145.78M -89.33M
    Depreciation & Amortization
    		 629K 258K

    Add to Watchlist